Core Viewpoint - The collaboration between LianKang Biotechnology Group, Wenzhou Medical University National Engineering Research Center, and Wenzhou Ouhai District People's Government aims to enhance research and development in the fields of skin, ophthalmology, and metabolic-related diseases, accelerating strategic implementation processes [1][2] Group 1: Collaboration Details - A tripartite strategic cooperation agreement has been signed to establish the "LianKang-Wenzhou Medical University Translational Medicine Joint Innovation Laboratory" [1] - The collaboration will leverage each party's strengths in research, industry, and policy to conduct comprehensive cooperation from basic research to clinical transformation and industrialization [2] Group 2: Research Focus - The partnership will explore the synergistic mechanisms of epidermal growth factor (EGF) and fibroblast growth factor (FGF) in regulating metabolic homeostasis, improving insulin sensitivity, and promoting tissue repair [1] - New formulations and delivery systems will be developed targeting diseases such as non-alcoholic steatohepatitis (NASH) and asthma, addressing significant unmet clinical needs in these areas [1] Group 3: Strategic Implications - This collaboration is expected to enhance the group's research efficiency and success rates in the biopharmaceutical innovation sector, shortening product development cycles [2] - The partnership will also facilitate the expansion of existing products into more clinical applications, reinforcing the group's competitive edge in the EGF/FGF niche [2] - The board views this collaboration as a key initiative to deepen the "government-university-enterprise" synergy and integrate into national-level innovation platforms, significantly accelerating the development and transformation of cutting-edge innovation pipelines [2]

Core Viewpoint - The strategic partnership between Link Health Biotechnology Group, Wenzhou Medical University National Engineering Research Center, and Wenzhou Ouhai District People's Government aims to enhance research and development in the fields of skin, ophthalmology, and metabolic-related diseases, accelerating the implementation of the company's strategic initiatives [1][2] Group 1 - The collaboration will leverage the strengths of each party in research, industry, and policy to conduct comprehensive cooperation from basic research to clinical translation and industrialization in the application of growth factor drugs in regenerative medicine [1][2] - The partnership will explore the synergistic mechanisms of epidermal growth factor (EGF) and fibroblast growth factor (FGF) in regulating metabolic homeostasis, improving insulin sensitivity, and promoting tissue repair, with the goal of developing new compound formulations and delivery systems for diseases such as non-alcoholic steatohepatitis (NASH) and asthma [1][2] - This collaboration is expected to fill treatment gaps in multiple niche indications and unlock clinical and commercial value in the vast chronic disease market [1] Group 2 - The Wenzhou Medical University National Engineering Research Center is a leading independent entity focused on basic research and new drug development in the field of growth factor drugs, under the leadership of Academician Li Xiaokun from the Chinese Academy of Engineering [2] - The partnership is anticipated to enhance the company's R&D efficiency and success rate in the biopharmaceutical innovation sector, shorten product development cycles, and strengthen competitiveness in the EGF/FGF niche market [2] - The board views this collaboration as a key initiative to deepen the "government-university-enterprise" synergy and integrate into a national-level innovation platform, significantly accelerating the R&D and translation of cutting-edge innovation pipelines [2]

Core Viewpoint - The approval of the listing application for Isavuconazole capsules marks a significant milestone for the company in the antifungal treatment sector, expected to provide effective and safe treatment options for patients with invasive fungal infections by the second half of 2026 [1][2]. Group 1: Product Development and Market Position - Isavuconazole is a new triazole antifungal drug with broad-spectrum antibacterial activity, working by inhibiting the synthesis of ergosterol in fungal cell membranes [1]. - The launch of Isavuconazole capsules will create a synergistic effect with the existing product Voriconazole, further solidifying the company's leadership position in the antifungal market [1]. - The company has established a customized production line for Isavuconazole, ensuring high-quality production and stable supply, which provides a competitive advantage [2]. Group 2: Market Growth and Strategic Planning - The global antifungal drug market is expected to grow significantly, with the Chinese market projected to reach approximately 30 billion RMB by 2030, reflecting a compound annual growth rate of over 10% [2]. - The launch of Isavuconazole capsules will enrich the company's product pipeline and contribute to sales growth, aligning with the increasing demand for innovative and effective therapies [2]. - The company has also received approval for its ophthalmic drug, Diquafosol Sodium Eye Drops, enhancing its ophthalmic product line and providing diverse treatment options for dry eye patients [3].

UNI-BIO SCIENCE GROUP LIMITED 聯 康 生 物 科 技 集 團 有 限 公 司* （於開曼群島註冊成立之有限公司） （股份代號：0690） 香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 佈 之 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公佈全部或 任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 * 僅供識別 – 1 – 戰 略 性 擴 充 銷 售 團 隊 ， 整 合 線 上 線 下 渠 道 資 源 ， 覆 蓋 醫 院 、 藥 房 及 主 流 電 商 平 台。從而保證金因康®快速提升市場滲透率和競爭力。 乾眼症患者群體和市場規模持續擴大。相關數據顯示，中國乾眼症市場約有超過 3.6億患者，市場規模預計將以28.4 %的複合年增長率快速擴張，至二零三零年突 破 人 民 幣 420 億 元 。 並 且 ， 隨 著 患 者 對 治 療 便 捷 性 及 安 全 性 需 求 的 提 升 ， 金 因 康®將為應對廣泛存在但尚未被充分滿足的醫療需求，提供強有力的解決方案。 展望未來 ...